Questions?
(888) 391-1315

NUVARING & BLOOD CLOTS

NuvaRing has been linked to blood clots and has recently settled cases involving DVT or Pulmonary Embolism.

NuvaRing Information

NuvaRing cases have recently settled and we have no manufacturer information on accepting any future cases related to blood clot injuries.

NuvaRing is a popular vaginal ring implant device developed by Organon and sold by Merck & Co. In 2001, the device was approved by the FDA and marketed as a safer, more convenient contraception alternative to birth control pills. Millions of women have used this device.

However, medical experts now warn that vaginal ring implants like NuvaRing may be linked to serious health risks. Several studies have suggested that the device is responsible for increased risks for blood clots, which can lead to painful and dangerous conditions, such as pulmonary embolism, deep vein thrombosis, and stroke.

The NuvaRing device is inserted into the vagina once every three weeks, and works by delivering a low dose of hormones directly and constantly into the bloodstream. However, leading medical journals – and the FDA – have published research suggesting that vaginal rings may present a greater risk for blood clots.

The FDA has received over 5,000 reports of serious adverse medical incidents in which NuvaRing was identified as the primary cause for the incident. The top three adverse events are pulmonary embolism, deep vein thrombosis, and irregular bleeding.

The FDA has received over 5,000 reports of serious adverse medical incidents in which NuvaRing was identified as the primary cause for the incident. The top three adverse events are pulmonary embolism, deep vein thrombosis, and irregular bleeding.

nuvaring device
nuvaring blood clots

nuvaring Side Effects

In the device’s safety information, Merck lists side effects such asvaginitis, headaches, upper respiratory infection, sinusitis, nausea, vaginal discharge, and weight gain.

However, recent studies have revealed more serious side effects:

  • Blood clots
  • Stroke
  • Deep vein thrombosis (DVT)
  • Pulmonary embolism

The FDA has reported over 5,000 cases of these serious adverse effects from using NuvaRing.

The NuvaRing device works by releasing hormones directly and continuously into the bloodstream. This method can result in a higher overall hormone dose, in turn raising potassium levels in the blood and increasing the risk for blood clots and stroke.

Warnings

Since NuvaRing's release to market in 2001, the FDA has received more than 5,000 reports of blood clot injuries among women using the device. In 2011, the FDA issued the first NuvaRing warning, a study showing that vaginal ring contraceptives could raise the risk for blood clots, DVT, and pulmonary embolism by up to 56 percent when compared with low-dose estrogen birth control pills.

Leading medical publications have also issued warnings against NuvaRing. In 2012, the British Medical Journal released a study showing that vaginal rings similar to NuvaRing could increase the risk of blood clots by as much as 90 percent over oral contraceptives. The New England Journal of Medicine published research linking vaginal ring contraceptives to a 250 to 300 percent increased risk of blood clots.

Recall

Leading medical journals and the FDA have released studies showing that vaginal ring devices like NuvaRing increase risk of blood clots and other serious conditions. Yet, there has not been a NuvaRing recall. Experts fear that many women using the device may not realize that they are at such high risk for developing dangerous health conditions.

Assistance is available. Speak with a patient advocate today.
GET ASSISTANCE